Molecular Templates (NASDAQ:MTEM) Announces Quarterly Earnings Results

Molecular Templates (NASDAQ:MTEM) posted its earnings results on Wednesday. The biotechnology company reported $0.08 EPS for the quarter, reports. Molecular Templates had a negative net margin of 57.92% and a negative return on equity of 2,594.26%. The company had revenue of $11.09 million for the quarter.

Molecular Templates Stock Performance

Shares of MTEM stock opened at $1.45 on Friday. The firm has a market cap of $9.55 million, a P/E ratio of -0.94 and a beta of 1.15. The firm’s 50 day moving average price is $1.91 and its 200-day moving average price is $3.38. Molecular Templates has a one year low of $1.27 and a one year high of $9.45.

Insider Activity at Molecular Templates

In other news, major shareholder Target N. V. Biotech purchased 250,000 shares of the firm’s stock in a transaction on Tuesday, April 2nd. The shares were bought at an average cost of $2.35 per share, for a total transaction of $587,500.00. Following the completion of the purchase, the insider now directly owns 1,279,820 shares of the company’s stock, valued at $3,007,577. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 18.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Molecular Templates

An institutional investor recently bought a new position in Molecular Templates stock. Monashee Investment Management LLC purchased a new position in shares of Molecular Templates, Inc. (NASDAQ:MTEM) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 141,841 shares of the biotechnology company’s stock, valued at approximately $896,000. Monashee Investment Management LLC owned 2.64% of Molecular Templates at the end of the most recent reporting period. Institutional investors and hedge funds own 95.47% of the company’s stock.

About Molecular Templates

Molecular Templates, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB).